Sinusitis Treatment Market Report 2026

The sinusitis treatment market size has grown strongly in recent years. It will grow from $3.13 billion in 2025 to $3.33 billion in 2026 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to high prevalence of sinusitis, limited treatment options, reliance on corticosteroids, growing ENT specialty clinics, early adoption of minimally invasive procedures.

The sinusitis treatment market size is expected to see strong growth in the next few years. It will grow to $4.1 billion in 2030 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to development of biologics and targeted therapies, increasing adoption of balloon sinuplasty, expansion of outpatient ENT care, integration with telemedicine, growth in chronic rhinosinusitis awareness programs. Major trends in the forecast period include rise in biologics for chronic sinusitis, growth in balloon sinuplasty procedures, adoption of steroid-eluting sinus implants, increasing use of nasal irrigation devices, expansion of telemedicine ENT consultations.

The rising prevalence of respiratory conditions such as asthma is expected to drive the growth of the sinusitis treatment market in the coming years. Asthma is a chronic respiratory disorder marked by inflammation and narrowing of the airways, causing recurring episodes of wheezing, shortness of breath, chest tightness, and coughing. The incidence of asthma is increasing due to factors such as environmental pollution, allergen exposure, genetic susceptibility, urbanization, lifestyle changes, and respiratory infections. Sinusitis treatments help clear nasal blockages and improve sinus drainage, reducing postnasal drip and lowering the risk of secondary infections that can impact the respiratory system. For example, in December 2023, the National Center for Biotechnology Information, a US-based government agency, reported that the number of COPD cases is projected to rise by 112 million, reaching 592 million by 2050, representing 9.5% of the eligible population. Therefore, the growing prevalence of asthma is fueling the growth of the sinusitis treatment market.

Major companies in the sinusitis treatment market are focusing on developing innovative therapies such as steroid nasal sprays to improve treatment efficacy, minimize side effects, and offer convenient dosing options. Steroid nasal sprays, also known as corticosteroid sprays, are anti-inflammatory medications administered via the nasal route to treat various conditions. For instance, in March 2024, Optinose Inc., a US-based pharmaceutical company specializing in nasal polyp treatment, launched XHANCE, a combination drug-device system utilizing the Exhalation Delivery System (EDS), approved by the U.S. Food and Drug Administration. XHANCE is designed to deliver topical steroids to the deep and upper regions of the nasal cavity where the sinuses ventilate and drain. It is indicated for treating chronic rhinosinusitis, with or without nasal polyps, in patients aged 18 and older.

In April 2024, Integra LifeSciences, a US-based medical technology company, acquired Acclarent, Inc. for an undisclosed amount. This acquisition allows Integra LifeSciences to strengthen its ENT (ear, nose, and throat) product portfolio, expand its global presence in minimally invasive surgical solutions, and create growth opportunities across its neurosurgery and precision surgical business segments. Acclarent, Inc. is a US-based medical device company specializing in balloon dilation and minimally invasive instruments for ENT procedures.

Major companies operating in the sinusitis treatment market are Johnson & Johnson, Pfizer Inc, Bayer AG, GlaxoSmithKline Plc, Teva Pharmaceutical Industries Ltd, Baxter International Inc, Fresenius Kabi AG, Boehringer Ingelheim GmbH, Perrigo Company plc, Dr Reddys Laboratories Ltd, Aurobindo Pharma, Cipla Ltd, Hikma Pharmaceuticals Plc, Apotex Inc, Lupin Pharmaceuticals Inc, Bionorica SE, Wockhardt Ltd, Zydus Cadila Ltd, Intersect ENT Inc, Novartis AG, Sanofi S A, Alembic Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd, Abbott Laboratories.

North America was the largest region in the sinusitis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sinusitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sinusitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the sinusitis treatment market by raising prices for imported antibiotics, corticosteroids, nasal sprays, and surgical instruments used in both medical and surgical management. Hospitals and retail pharmacies in Asia-Pacific and emerging regions are most affected due to dependence on global pharmaceutical supply chains. These higher costs can limit access to advanced drug and surgical therapies for chronic sinusitis. However, tariffs are encouraging domestic drug manufacturing and formulation, improving long-term availability in the sinusitis treatment market.

The sinusitis treatment market research report is one of a series of new reports that provides sinusitis treatment market statistics, including sinusitis treatment industry global market size, regional shares, competitors with a sinusitis treatment market share, detailed sinusitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the sinusitis treatment industry. This sinusitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Sinusitis treatment involves a variety of methods and therapies aimed at relieving the symptoms of the condition. Sinusitis, which is the inflammation or infection of the sinuses, is managed using treatment strategies tailored to the severity and underlying cause, as well as the individual’s overall health and medical history.

The main types of treatments for sinusitis include analgesics, antibiotics, antihistamines, surgery, corticosteroids, sulfonamides, and quinolones. Analgesics are medications that relieve pain without causing unconsciousness. The condition can be classified into acute sinusitis, sub-acute sinusitis, and chronic sinusitis. Treatment is administered via topical, nasal, oral, and injectable routes, and is distributed through online pharmacies, retail pharmacies, and hospital pharmacies.

The sinusitis treatment market includes revenues earned by entities by diagnostic tests, medications, nasal irrigation and saline rinses, surgical treatments and related nasal drug delivery devices, acupressure, acupuncture, and facial massage. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.